Although NLR can be used to distinguish responders from non-responders in patients with NSCLC treated with anti–PD-1 therapy as reported in the literature, its AUC is not as good as that of PD-1+ IFN-γ+ cell percentages of CD8+ T cells. This evidence concerns the gene CD8A and non-small cell lung carcinoma.